BioTek Instruments Awarded Patent

by VBSA-admin on September 6, 2023

Hybrid Technology™ in Multi-Mode Microplate Readers
BioTek has been awarded US patent 8,218,141 covering the combination of two alternate paths for light within the same analytical instrument. Known as Hybrid Technology™, the patented functionality is available in BioTek’s Synergy™ NEO HTS Multi-Mode Microplate Reader and in the Synergy H4 and H1 Hybrid Multi-Mode Microplate Readers.

Using Hybrid Technology, light can be directed to and from the microplate samples through a filter-based optical system or through a monochromator-based optical system for wavelength selection. This two-optical-path system provides optimal performance and flexibility for a wide range of applications in fluorescence microplate assays. BioTek’s Synergy readers are modular platforms that can include Fluorescence Intensity, UV-Vis Absorbance, Luminescence, TRF, TR-FRET and FP detection modes.

BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. In 2011, BioTek received the North American New Product Innovation Award for Workflow Solutions in Life Sciences from Frost & Sullivan. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process, provide rapid and cost-effective industrial analysis, and to enable sensitive and accurate quantification of a wide range of molecules across diverse applications.

About BioTek Instruments
BioTek Instruments, Inc. is a global leader in the development, manufacture and sale of microplate instrumentation and software. The company’s origins date back to 1968, when Dr. Norman Alpert, a physiologist at the University of Vermont Medical College, founded BioTek. Dedicated to providing test equipment solutions for the hospital safety and quality assurance markets, BioTek’s Biomedical Division grew to become one of the largest and most successful companies in the field.

[Part of the September 2012 Newsletter, See More in the Archives.]

Previous post:

Next post: